Αρχική World News FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell... World News FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma Από Ogkologos - 27 Μαΐου, 2026 312 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BGB-11417-201 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ AI for early cancer detection: where are we now? Could virtual reality become a reality in cancer supportive care? EMA recommends granting a marketing authorisation for daraxonrasib MOST POPULAR Neoadjuvant Docetaxel, Oxaliplatin, and S-1, as Part of Perioperative Chemotherapy, Prolongs... 19 Αυγούστου, 2024 ESMO Highlights the Importance of a Strong EU Commitment Towards Robust... 29 Μαΐου, 2026 A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and... 21 Σεπτεμβρίου, 2021 In the Name of Pinkness 8 Οκτωβρίου, 2020 Φόρτωση περισσοτέρων HOT NEWS 4 Tips from Oncology Dietitians for Healthier Eating During Cancer FDA Approves Cabozantinib for Differentiated Thyroid Cancer COVID-19 Vaccine: Distribution and Administration What Are Social Determinants of Health and How Do They Affect...